<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034810</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 201802 SILK VISTA</org_study_id>
    <nct_id>NCT04034810</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment</brief_title>
  <acronym>FIRST</acronym>
  <official_title>Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment, an Observational, Prospective, Single Arm, International, Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balt Extrusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balt Extrusion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FIRST study is an observational, prospective, multi-center, international, single-arm,&#xD;
      study. The aim of the study is to collect safety and efficacy information on the use of the&#xD;
      silk vista and silk vista baby flow diverter in order to assess clinical safety and&#xD;
      performance of the device for treating intracranial aneurysms.&#xD;
&#xD;
      All patients with intracranial aneurysm ruptured or unruptured, whatever the localization of&#xD;
      the aneurysm, and treated with silk vista or silk vista baby, will be consecutively enrolled&#xD;
      in the study.&#xD;
&#xD;
      The patient's inclusion and follow up in the study will occur as part of their usual standard&#xD;
      of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.</measure>
    <time_frame>At 12-months (-3 / + 6 months) post procedure</time_frame>
    <description>Characterized by the rate of the permanent neurologic deficits and procedure related mortality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbi-mortality of silk vista and silk vista baby in the treatment of intracranial aneurysms.</measure>
    <time_frame>At 12-months (-3 / + 6 months) post procedure</time_frame>
    <description>Characterized by the clinical outcome assessed by mRS of the permanent neurologic deficits and procedure related mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At T0</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At hospital discharge</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>Up to 30 days (-10 / + 21 days) post- procedure.</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At 6 months (-2/+3 months) post- procedure.</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At 12 months (-3/+6 months) post- procedure.</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At 3 years post procedure</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of silk vista and silk vista baby</measure>
    <time_frame>At 5 years post procedure</time_frame>
    <description>Assessed by the rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>At T0</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>At hospital discharge</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>Up to 30 days (-10 / + 21 days) post- procedure.</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>Up to 6 months (-2/+3 months) post- procedure</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>Up to 12 months (-3 / + 6 months) post procedure</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>Up to 3 years post procedure</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of silk vista and silk vista baby</measure>
    <time_frame>Up to 5 years post procedure</time_frame>
    <description>Assessed by aneurysm occlusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical procedure</measure>
    <time_frame>At T0</time_frame>
    <description>The practices related to the use of silk vista baby will be describe</description>
  </secondary_outcome>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intracranial aneurysm treated with Silk vista and silk vista baby</intervention_name>
    <description>Patients with intracranial aneurysm(s) intended to be treated with the silk vista and silk vista baby according to standard of care.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an intracranial aneurysm treated with silk vista and silk vista baby.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with intracranial aneurysms intended to be treated with the silk vista and&#xD;
             silk vista baby (decision of use silk vista and silk vista baby is done independently&#xD;
             and prior to the participation of the patient in the study)&#xD;
&#xD;
          2. Patients with recanalized aneurysms previously treated with coils exclusively are also&#xD;
             eligible.&#xD;
&#xD;
          3. In case of multiple aneurysms, only treatment with silk vista and silk vista baby are&#xD;
             allowed (between the initial index procedure to the 12 months follow up visit)&#xD;
&#xD;
          4. Patient ≥ 18 years, who signed an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient presenting with contra-indications to the use of silk vista and silk vista&#xD;
             babyaccording to the IFU (Instruction for Use).&#xD;
&#xD;
          2. Recanalized aneurysms initially treated with stent (including stent assisted coiling)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Martinez Galdamez, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario de Valladolid (HCUV), Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saliha HADDAG</last_name>
    <phone>+33 1 39 34 90 81</phone>
    <email>saliha.haddag@baltgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Monika Killer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC Saint Joseph Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Brisbois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Ozretic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Florent Gariel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Gentric Jean Christophe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Neurologique</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Omer Eker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen, Radiologie interventionelle</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Charlotte Barbier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Spelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Mounayer Charbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piotin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michel Piotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nader Sourour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Chalre Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Papagiannaki Chrysanthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munich LMU University</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Liebig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Enrique Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shadi Jahshan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niguarda Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edoardo Boccardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paolo Reminda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cà Foncello Hospital</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Di Paola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa maria della misericordia hospital</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Massimo Sponza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 G</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joost Dr Vries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de cruces</name>
      <address>
        <city>Baracaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Maria Gonzalez Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramon y Cajal hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Carlos Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopsital universidad puerta de hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aurelio Vega Astudillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unversitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro Vega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Martinez Galdamez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

